Article Correctness Is Author's Responsibility: APEIRON’s respiratory compound to start pilot clinical trial in COVID-19

(MC Services AG) An Investigator Initiated Trial (IIT) to start in China, with an international team of experts from China, Austria, and Canada.Twenty-four patients with severe COVID-19 to be treated in a randomized, dual-arm trial with Apeiron's ACE2 drug product APN01.APN01 was previously proven to be safe and well tolerated in Phase I and Phase II clinical trials.With its unique ACE2 approach APN01 offers an alternative treatment option to other approaches currently in development.